HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to evaluate the safety and efficacy of two doses of
GT005 administered as a single subretinal injection in subjects with geographic atrophy
secondary to age-related macular degeneration (AMD).